[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356857-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-356857-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","seminal-fluid-biomarkers-for-early-cancer-detection-a-systematic-review","Seminal Fluid Biomarkers for Early Cancer Detection - A Systematic Review","","The early detection of prostate and testicular tumors remains challenging because standard diagnostics can lack sensitivity and yield ambiguous findings. Seminal fluid is a biologically rich medium that mirrors male reproductive tissues and may enable non-invasive molecular biomarkers. This study systematically evaluates evidence on cell-free DNA, RNA, proteins, and metabolites in seminal fluid and assesses their potential to improve early detection of male reproductive cancers. Using PRISMA-guided methods, 42 clinical studies were synthesized, showing tumor-associated molecular changes and variable diagnostic performance, alongside notable heterogeneity and limited prospective validation.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/seminal-fluid-biomarkers-for-early-cancer-detection-a-systematic-review/356857/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/seminal-fluid-biomarkers-for-early-cancer-detection-a-systematic-review/356857.png","ImageObject",300,407,{"name":42,"@type":43},"Pentious","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Why is seminal fluid considered promising for early cancer biomarkers?","Question",{"text":63,"@type":64},"Seminal fluid is a biologically rich medium that reflects the molecular state of male reproductive tissues, making it a candidate source for non-invasive biomarkers relevant to prostate and testicular cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which biomarker types were evaluated in the systematic review?",{"text":68,"@type":64},"The review evaluates evidence for cell-free DNA, RNA, proteins, and metabolites in seminal fluid, including microRNAs, other non-coding RNAs, and metabolomic signatures.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance levels were reported across studies?",{"text":72,"@type":64},"Across biomarker classes, diagnostic performance varied but included sensitivities up to 80–100% for cell-free DNA markers and multimarker models with AUCs around 0.85–0.93 in several studies.",{"name":74,"@type":61,"acceptedAnswer":75},"What limitations prevent routine clinical implementation of seminal fluid biomarkers?",{"text":76,"@type":64},"The evidence is largely exploratory and methodologically heterogeneous, with variable risk of bias and a lack of large prospective validation cohorts using standardized protocols.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},356857,1790557775,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Systematic Review  \nSeminal Fluid Biomarkers for Early Cancer Detection: A Systematic Review  \nGuzel R. Sagitova 1,2, Anna V. Slizova 1, Andrey O. Morozov 3, Anastasia S. Fatyanova 2, Majid Ebrahimi Warkiani 4, Andrei V. Zvyagin 5,6, * and Alexey S. Rzhevskiy 1,7  \nAcademic Editors: Silvia Di Agostino, Vittoria Rago and Anna Perri  \nReceived: 26 February 2026  \nRevised: 16 April 2026  \nAccepted: 21 April 2026  \nPublished: 23 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Institute of Molecular Theranostics, Sechenov First Moscow State Medical University, 119991 Moscow, Russia; [sagitova_g_r@staff.sechenov.ru](sagitova_g_r@staff.sechenov.ru) (G.R.S.)  \n2 Department of Oncology, Radiotherapy and Reconstructive Surgery, Institution of Clinical Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia  \n3 Institute for Urology and Reproductive Health, Sechenov University, 119991 Moscow, Russia  \n4 School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia  \n5 Research Center for Translational Medicine, Sirius University of Science and Technology, 354340 Sochi, Russia  \n6 Australian Research Council Centre of Excellence for Nanoscale Biophotonics, Macquarie University, Sydney, NSW 2109, Australia  \n7 Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, 117198 Moscow, Russia  \n* Correspondence: [andrei.zvyagin@mq.edu.au](andrei.zvyagin@mq.edu.au)  \nAbstract  \nBackground: The early detection of prostate and testicular tumors remains challenging as standard diagnostic tools often lack sensitivity and produce ambiguous results. Seminal fluid is a biologically rich medium that closely reflects the state of male reproductive tissues and has therefore emerged as a promising source of non-invasive molecular biomarkers. Objective: This study aimed to critically evaluate the evidence regarding cell-free DNA, RNA, proteins and metabolites in seminal fluid, and to assess their potential for improving the early detection of male reproductive cancers. Methods: A systematic review was performed according to PRISMA guidelines. Comprehensive searches of the PubMed and Scopus databases were conducted to identify original clinical studies analyzing molecular biomarkers in seminal fluid from patients with prostate or testicular tumors. For each study, data were extracted on biomarker types, cohort characteristics, analytical methods and diagnostic performance. Results: Forty-two eligible studies were included, covering multiple biomarker classes. Most were observational, single-center investigations classified as level 3b evidence. Across the different types of biomarkers, seminal fluid was associated with tumor-associated molecular changes. Alterations in the concentration, fragmentation and methylation patterns of cell-free DNA (e.g., GSTP1, RARβ2, LGALS3 and OCT3/4) distinguished malignant from benign conditions with sensitivities of up to 80–100% . RNAbased markers, including microRNAs, small non-coding RNAs, and tRNA fragments, showed improved performance in several studies, with multimarker models achieving areas under the curve (AUCs) of 0.85–0.93 . Proteomic analyses identified high-specificity candidates such as TGM4, AMACR, PROS1 and DKK3 . Metabolomic profiling further strengthened the diagnostic potential; reduced seminal citrate outperformed prostatespecific antigen (AUC 0.748 vs. 0.548), and reproducible shifts in amino acid and lipid profiles were observed in testicular tumors. However, substantial heterogeneity in study design, patient selection, and analytical platforms was observed. Risk of bias varied, and large prospective validation cohorts were lacking. Conclusions: Current evidence suggests that seminal fluid cont","cbCaibFh9aVld4gQ","https://ap.wps.com/l/cbCaibFh9aVld4gQ","pdf",666878,27,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why is seminal fluid considered promising for early cancer biomarkers?\",\"answer\":\"Seminal fluid is a biologically rich medium that reflects the molecular state of male reproductive tissues, making it a candidate source for non-invasive biomarkers relevant to prostate and testicular cancers.\"},{\"question\":\"Which biomarker types were evaluated in the systematic review?\",\"answer\":\"The review evaluates evidence for cell-free DNA, RNA, proteins, and metabolites in seminal fluid, including microRNAs, other non-coding RNAs, and metabolomic signatures.\"},{\"question\":\"What diagnostic performance levels were reported across studies?\",\"answer\":\"Across biomarker classes, diagnostic performance varied but included sensitivities up to 80–100% for cell-free DNA markers and multimarker models with AUCs around 0.85–0.93 in several studies.\"},{\"question\":\"What limitations prevent routine clinical implementation of seminal fluid biomarkers?\",\"answer\":\"The evidence is largely exploratory and methodologically heterogeneous, with variable risk of bias and a lack of large prospective validation cohorts using standardized protocols.\"}]","Seminal Fluid Biomarkers for Early Cancer Detection - A Systematic Review | PDF",1790127714,68,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2f76fd855a2650fa20c3af75158c830.webp",983,1390,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d3f0b6e18d26942796b0f785ef52e04.webp",982,1388,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c7b833a8e47687dc9726507c01a78ea.webp",981,1387,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d35229b5906add6264b3862c178c90b.webp",980,1385]